证券时报网讯，多只港股通标的遭遇调整，平安好医生以11.78%的跌幅领跌，紧随其后的是汇量科 技，跌幅达到8.59%。 第四范式和金山云的跌幅也较为显著，分别为7.55%和7.73%。 科济药业-B和微创机器人-B同样表现不佳，跌幅分别为7.36%和6.28%。 锅圈、康诺亚-B、阅文集团和宜搜科技的跌幅超过5%。 校对：廖胜超 ...

PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED （於開曼群島註冊成立的有限公司） 2024 年中期報告 平安健康醫療科技有限公司 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 股份代號 :1833.HK 平安健康秉承「省心、省時、又省錢」的價值主張，依託完善的供應商網路、領先的服務 體系、豐富的支付方資源及強大的生態賦能等核心競爭優勢，不斷深化管理式醫療模式 的探索實踐。通過堅持踐行獨特商業模式，持續深入洞察用戶訴求，用心做好產品打磨 和服務提升，致力於讓每一家企業擁有幸福職場，讓每一個家庭擁有專屬醫生，讓每一 位用戶擁有平安健康。 此中期報告（「中期報告」）（英文及中文版）已於本公司網站 www.pagd.net 和披露易網 站 www.hkexnews.hk 上登載。 若希望收取公司通訊之印刷本，股東可隨時書面通知香港證券登記處， 郵寄地址為香港灣仔皇后大道東183號合和中心17 M 樓，或通過電郵地 址 pagd.ecom @ computershare.com.hk ，並註明股東的姓名、地址以及收 ...

浦银国际研究 公司研究 | 医药行业 平安好医生（1833.HK）：1H24 超预期实现 盈利，短期关注收入恢复增长时点及利润 率改善空间 公司 1H24 实现扭亏为盈，超出市场预期，但收入端表现仍显乏力，盈 利更多来自期间费用率的改善。C 端业务因战略调整继续对收入增长 有所拖累，但 1H24 C 端收入占比已降至 13%，公司收入已接近重回正 增长。但我们仍在等待更确定的公司收入重回正增长的时点以及利润 率逐步扩张的信号，维持"持有"评级，调整目标价至 11.4 港元。 1H24 超预期实现扭亏为盈，但收入端表现仍显乏力。1H24 年收入 同比-6%至人民币 20.9 亿元；毛利率同比持平于 32.3%；三大期间费 用率 1H24 同比减少 18pcts，带动公司 1H24 归母净利/经调整净利同 比扭亏为盈至 5,665 万/8,974 万元（vs Visible Alpha 一致预期：亏损 5,300 万元），净利润层面表现超出市场预期。 F 端稳健增长，公司继续挖掘集团客户资源。公司 F 端（金融客户） 1H24 收入同比+3%至人民币 11.2 亿元，增速相对稳健。公司继续挖 掘平安集团综合金融业 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1833） 截至2024年6月30日止六個月期間 未經審計中期業績公告 平安健康醫療科技有限公司（「本公司」）董事會（「董事會」）欣然公佈本公司及其 附屬公司（「本集團」）截至2024年6月30日止六個月期間未經審計中期業績公告。 本公告刊載本公司2024年中期報告（「中期報告」）全文，並符合香港聯合交易所有 限公司（「聯交所」）證券上市規則中有關中期業績初步公告附載的資料之要求。 公司審計及風險管理委員會已審閱本集團截至2024年6月30日止之六個月期間中 期業績。 本公告將於聯交所網站 www.hkexnews.hk 及本公司網站 www.pagd.net 發佈。截至 2024年6月30日止六個月期間中期報告將適時於上述聯交所及本 ...

Financial Performance - Ping An Health's revenue in 2023 reached RMB 10.2 billion, representing a year-on-year growth of 15%[1] - The company's net profit for 2023 was RMB 1.5 billion, with a net profit margin of 14.7%[1] - Total revenue for 2023 was RMB 4,673.6 million, a decrease of 24.7% compared to 2022 (RMB 6,205.1 million)[17] - F-end strategic business revenue grew by 14.8% YoY to RMB 2,204.7 million in 2023, with a 4.5% increase in the second half compared to the first half[18] - B-end strategic business revenue surged by 81.2% YoY to RMB 1,078.5 million in 2023, with a 40.1% increase in the second half compared to the first half[18] - Gross profit margin improved by 5.4 percentage points to 32.3% in 2023, up from 26.9% in 2022[18] - Net loss narrowed significantly to RMB 334.9 million in 2023, a decrease of 47.6% compared to RMB 639.6 million in 2022[17][18] - The company's gross profit margin increased by 5.4 percentage points year-on-year in 2023, and net losses narrowed significantly by 47.6%[12] - Total revenue for 2023 was RMB 4,673.6 million, a decrease of 24.7% compared to RMB 6,205.1 million in 2022[42] - Medical services revenue decreased by 19.9% to RMB 2,075.4 million, while health services revenue decreased by 28.1% to RMB 2,598.2 million[42][43][45] - Gross profit margin for medical services increased by 4.9 percentage points to 40.0%, and for health services increased by 5.0 percentage points to 26.1%[42][43][45] - Net loss for 2023 was RMB 334.9 million, a significant reduction from RMB 639.6 million in 2022[52] - Adjusted net loss for 2023 was RMB 315.1 million, a decrease of RMB 561.6 million compared to 2022[52][53] - The total loss of the Group's operating entities for the year ended December 31, 2023, was approximately RMB 129.5 million[163] User and Client Growth - Ping An Health's user base grew to 68 million, an increase of 12% compared to the previous year[2] - The company's enterprise clients increased by 25% to 1,200 in 2023[2] - The company's mobile app monthly active users (MAU) reached 12 million, a 20% increase year-on-year[2] - LTM paying users for strategic business reached 32 million, a 10.7% increase compared to 29 million in 2022[19] - B-end LTM paying users for strategic business grew by 75.0% to 5 million in 2023, up from 3 million in 2022[19] - B-end cumulative enterprise clients served increased by 54.2% to 1,508 in 2023, compared to 978 in 2022[19] - The number of paying users served in the past 12 months was approximately 40 million, a 7.3% decrease compared to the previous year[103] - B2B strategic business served over 5.1 million paying users, while F2B strategic business served approximately 26.3 million paying users[103] Technology and Innovation - Ping An Health's AI-driven medical consultations accounted for 35% of total consultations in 2023[10] - The company invested RMB 500 million in R&D for new healthcare technologies in 2023[10] - The AI health manager developed by the company has improved chronic disease management efficiency by up to 5 times[12] - The company's medical AI technology covers approximately 36,000 diseases and 15 million questions, achieving 100% AI empowerment in all service links[37] - The company has obtained ISO27001, ISO27701, and ISO27799 certifications, and is the first in the internet medical field to receive the ISO27799 certification from DNV[37] Market Expansion and Strategy - The company plans to expand its overseas market presence, targeting Southeast Asia in 2024[10] - The company expanded its service network to cover 90% of China's tier-1 and tier-2 cities[10] - The company's cross-selling with Ping An Group's financial services contributed 30% of total revenue[11] - The company aims to support the Healthy China 2030 strategy and the construction of a carbon-neutral medical, health, and elderly care ecosystem[13] - The company's strategic focus on high-profitability businesses and digital transformation contributed to improved operational efficiency and reduced losses[18][21] - The company will deepen its managed care strategy, focusing on strategic business resources, leveraging Ping An Group's advantages in commercial insurance and corporate clients, and enhancing the value to payers[40] Operational Efficiency and Cost Management - Management expenses decreased by 15.3% to RMB 1,480.9 million in 2023, while sales expenses dropped by 25.4% to RMB 835.8 million[18] - Sales and marketing expenses decreased by 25.4% to RMB 835.8 million due to optimized resource allocation[47] - Administrative expenses decreased by 15.3% to RMB 1,480.9 million due to improved organizational efficiency[48] - The company has upgraded its organizational structure and operational efficiency, while acknowledging the need for further optimization in resource allocation[12] Elderly Care and Health Management - The "insurance + home-based elderly care" model has covered 54 cities across the country as of the end of September 2023[12] - The company has upgraded its "Easy Enterprise Health" product system, focusing on "physical examination +" and "health management +" solutions[12] - The company has established a service network covering consultation, diagnosis, treatment, and service, providing customers with a one-stop medical, health, and elderly care service[12] - The company has integrated medical, health, and elderly care service rights with financial/insurance product scenarios to provide users with full lifecycle services[14] - The company provides professional, comprehensive, high-quality, and one-stop enterprise health management services to B-end clients[15] - The company has linked online/offline medical, health, and elderly care service resources, with family doctors and elderly care managers as key hubs[14] - The home-based elderly care service covers 54 cities nationwide, with an ARPU of nearly 1,600 yuan as of the end of the reporting period[25] - The family doctor membership covers nearly 13 million people, with an annual average usage frequency of 3 times, an increase of 0.8 times compared to the same period last year, and an active service coverage rate of nearly 75%[33] - The company has established a "three-in-one" elderly care service system, linking over 500 home-based elderly care services, providing 7*24-hour service[33] Corporate Governance and Leadership - Guo Xiaotao, aged 52, joined the group as a non-executive director in March 2024 and has been serving as the co-CEO and deputy general manager of Ping An Group since 2019[68] - Cai Fangfang, aged 50, has been a non-executive director since May 2016 and currently serves as an executive director and deputy general manager of Ping An Group, overseeing multiple subsidiaries including Ping An Life Insurance and Ping An Bank[70] - Fu Xin, aged 44, joined the group as a non-executive director in March 2023 and currently serves as the deputy general manager of Ping An Group, with roles in Ping An Life Insurance and Ping An Asset Management[71] - Zhu Ziyang, aged 28, joined the group as a non-executive director in December 2021 and is responsible for the technology sector at Hopson Development Holdings Limited[72] - Tang Yunwei, aged 79, has been an independent non-executive director since May 2018 and has extensive experience in accounting and financial management, serving on multiple boards including China Jushi Co., Ltd[74] - Guo Tianyong, aged 55, has been an independent non-executive director since May 2018 and currently serves as an independent director for Kweichow Moutai Co., Ltd[74] - Zhou Yongjian, aged 73, has been an independent non-executive director since May 2018 and holds multiple board positions including at Xinyi Glass Holdings Limited and Beijing North Star Company Limited[76] - Li Dou was appointed as Executive Director, Chairman of the Board, and CEO on October 18, 2023[125] - Fang Weihao resigned as Chairman of the Board, Executive Director, and CEO on October 18, 2023 due to personal work arrangements[125] - Wu Jun was appointed as Executive Director on March 13, 2023[125] - The company's Board of Directors consists of 9 members, including 2 Executive Directors, 4 Non-Executive Directors, and 3 Independent Non-Executive Directors[193] - The company has adopted the Corporate Governance Code as its own governance framework since its listing on the Hong Kong Stock Exchange in May 2018[190] - The company deviates from the Corporate Governance Code by having the Chairman and CEO roles combined, held by Li Dou, due to his expertise and the company's operational structure[195] - The company has established strict internal control measures and high ethical standards to ensure compliance with laws and regulations[190] - The company has implemented a written code of conduct for insider trading and ensures all directors comply with the standard code for securities transactions[192] - The company's corporate culture emphasizes "convenience, time-saving, and cost-effectiveness" as its core value proposition[189] - The company's governance structure includes a Nomination and Remuneration Committee, Audit and Risk Management Committee, and Sustainability Committee[193] - The company has no intention to separate the roles of Chairman and CEO, believing the current structure maximizes shareholder interests[196] - The company has established multiple mechanisms to ensure the board receives independent perspectives, including annual reviews of these mechanisms[197] - The board structure mandates a minimum proportion and number of independent non-executive directors to maintain balance and independence[197] - Independent non-executive directors are evaluated for their independence, professional qualifications, and experience to ensure diverse decision-making[197] - The company provides mechanisms to support directors in fulfilling their duties, including timely access to meeting materials and seeking independent professional advice[197] - Independent non-executive directors play a crucial role in reviewing or approving matters, especially in cases of significant conflicts of interest[198] - The board adheres to listing rules requiring at least three independent non-executive directors, constituting at least one-third of the board[198] - The company has received confirmations from independent non-executive directors regarding their independence under listing rules[199] - Non-executive directors, including independent non-executive directors, have a designated term of three years, subject to re-election[200] - One-third of the directors must retire by rotation at each annual general meeting, with eligibility for re-election[200] - Directors appointed to fill temporary vacancies serve until the next general meeting and are eligible for re-election[200] Financial Resources and Investments - Cash and other liquid financial resources decreased to RMB 1,866.5 million as of December 31, 2023, from RMB 3,700.7 million in 2022[54] - Total available funds as of December 31, 2023, amounted to RMB 12,627.9 million, including cash and cash equivalents of RMB 1,866.5 million, restricted funds of RMB 84.8 million, time deposits of RMB 5,345.9 million, and financial assets of RMB 5,330.7 million[55] - Net cash used in operating activities for 2023 was RMB 282.9 million, a significant improvement compared to RMB 810.6 million in 2022[55] - Net cash used in investing activities for 2023 was RMB 1,486.1 million, primarily due to the purchase of financial products and time deposits amounting to RMB 11,398.4 million[55] - Capital expenditures for 2023 were RMB 42.96 million, mainly for the purchase of property, plant, and equipment, as well as intangible assets such as software[57] - The company's cash is primarily invested in highly liquid and low-risk instruments such as bank deposits and money market instruments, aiming to generate financial returns above the bank's current deposit rate[56] - The company did not hold any significant investments accounting for 5% or more of the group's total assets as of December 31, 2023[61] - No significant acquisitions or disposals of subsidiaries or joint ventures were made during the year ended December 31, 2023[63] - The company has no plans for significant investments or capital assets as of December 31, 2023[62] - The company did not have any assets pledged as collateral as of December 31, 2023[59] Employee and Compensation - The company had 1,753 employees as of December 31, 2023, with a competitive compensation system including cash salary, benefits, and long-term incentives[64] - The company had 1,753 employees as of December 31, 2023, with stable employee relations and no significant labor disputes[102] - The company granted 300,000 shares to Mr. Li Dou, Executive Director, Chairman, and CEO, with a vesting period from December 1, 2024, to December 1, 2027[119] - Mr. Fang Weihao, former Executive Director and CEO, had 153,345 shares remaining unexercised as of December 31, 2023, out of the originally granted 300,000 shares[119] - Mr. Wu Jun, Executive Director and President, had 228,345 shares remaining unexercised as of December 31, 2023, out of the originally granted 300,000 shares[119] - The top five highest-paid individuals collectively had 11,651,148 shares remaining unexercised as of December 31, 2023, out of the originally granted 73,331,415 shares[123] - Other grantees had 1,237,702 shares remaining unexercised as of December 31, 2023, out of the originally granted 14,287,098 shares[121] - The company granted 5,512,000 shares on December 19, 2022, with a vesting period from December 19, 2023, to December 19, 2026[123] - The company granted 3,079,200 shares on January 29, 2022, with a vesting period from January 29, 2023, to January 29, 2026[123] - The company granted 3,084,700 shares on August 24, 2021, with a vesting period from August 24, 2022, to August 24, 2025[123] - The company granted 1,812,100 shares on October 21, 2020, with a vesting period from October 21, 2021, to October 21, 2024[121] - The company granted 16,475,800 shares on March 31, 2017, with a vesting period from March 31, 2018, to March 31, 2021[121] - EIS stock options were granted on December 1, 2023, with a closing price of HKD 17.46 per share prior to the grant date[124] - The weighted average closing price before the exercise of EIS stock options was HKD 16.60 for directors, HKD 18.56 for the top five highest-paid individuals, and HKD 21.85 for other grantees[124] - As of December 31, 2023, Li Dou held 300,000 shares, representing approximately 0.03% of the company's total issued shares[135] - As of December 31, 2023, Wu Jun held 328,345 shares, representing approximately 0.03% of the company's total issued shares[135] - No stock-linked agreements were entered into or existed during the year ended December 31, 2023[127] - Directors are entitled to indemnification from the company's assets for losses or liabilities incurred in legal proceedings[131] - No management contracts were entered into or existed during the reporting period[132] Shareholder and Ownership Structure - Anxin directly holds 441,000,000 shares, representing 39.41% of the company's total issued shares as of December 31, 2023[137][138] - Hopson Development Holdings Limited holds 101,708,800 shares, representing 9.09% of the company's total issued shares[137][139] - Sounda Properties Limited holds 104,793,500 shares, representing 9.37% of the company's total issued shares[137][139] - The company had 26,627,312 EIS shares remaining for issuance under the employee incentive plan as of December 31, 2023, representing 2.38% of the issued shares[111] - The total number of unexercised EIS share options was 11,651,148 as of December 31, 2023[111] - The employee incentive plan is valid for 10 years from December 26, 2014, to December 25, 2024, with approximately 1 year remaining[113] Connected Transactions and Agreements - The annual cap for the product and service provision framework agreement with Ping An was RMB 8,700.0 million, with actual transaction amount of RMB 1,405.5 million for the year ended December 31, 2023[148] - The annual cap for the service procurement framework agreement with Ping An was RMB 1,638.0 million, with actual transaction amount of RMB 561.7 million for the year ended December 31, 2023[151] - The company renewed the service procurement framework agreement, effective from January 1, 2024, to December 31, 2026, covering services such as consulting, health management, and customer referral services[153] - The property leasing framework agreement was renewed, with the company expected to pay a total rent of no more than RMB 95.0 million in 2023, while the actual transaction amount was approximately RMB 29.3 million[154] - The company's financial services framework agreement with Ping An Bank had a maximum daily balance of deposits of RMB 10,000.0 million in 2023, with the actual maximum daily balance being approximately RMB

浦银国际研究 公司研究 | 医药行业 平安好医生（1833.HK）：业务结构调整基 阳景 本完成，毛利率及费用缩减推动减亏 浦 首席医药分析师 银 Jing_yang@spdbi.com 公司 2023 年收入略低于预期，但毛利率改善及费用缩减推动净亏损 (852) 2808 6434 国 好于预期。业务结构调整的工作（自 2021 年 11 月启动）已基本在 2023 际 年内完成，我们预计公司收入将在 2024E 重回增长。维持“持有”评 胡泽宇 CFA 级，下调目标价至15港元。 医药分析师 2023年收入略低于预期，但毛利率改善及费用缩减推动净亏损好于  ryan_hu@spdbi.com 预期。2023 年内公司继续出清低战略协同性、低毛利业务，导致收 公 (852) 2808 6446 入同比-24.7%至人民币 46.7 亿元，低于预期。毛利率的提升（同比 司 +5.3ppts）及费用缩减（销售费用/管理费用同比-25%/-15%）抵消了 2024年3月21日 研 收入下滑的影响，全年经调整净亏损同比减亏 64.1%至人民币 3.2亿 究 元，好于预期。 评级 F 端稳健增长，B端收入低基数下 ...

和資本市場的朋友們提醒各位將手機調至靜音模式我們的會議即將開始謝謝 好的那现在已经九点半了各位投资者分析师和资本市场的朋友们大家早上好感谢大家参加平安健康医疗科技有限公司2023年年报业绩发布会我是本次业绩发布会的主持人平安健康投资者关系部负责人王亦菲Aria 那首先请允许我为各位介绍一下参与本次业绩发布会的公司管理层他们是平安健康医疗科技有限公司董事会主席首席执行官李斗先生平安健康医疗科技有限公司总裁吴军先生平安健康医疗科技有限公司资深副总裁暨首席财务官赞洛琪女士 本次会议将由两部分组成第一部分中李斗先生将为大家分享公司的战略之后吴军先生将介绍公司2023年的经营亮点最后赞洛琪女士将回顾公司2023年的整体业绩和财务表现以及公司在ESG方面的举措 在会议的第二部分中管理层将回答大家的提问届时现场需要提问的投资者和分析师朋友请举手示意同时线上的投资者和分析师请按新意见提问 那在会议开始前我将宣读本次发布会的前瞻性陈述提示声明除历史事实陈述外本次业绩发布会包括演示材料中包含了某些前瞻性陈述所有本公司预计或预期未来可能或即将发生的包括但不限于预测目标估计及经营计划都属于前瞻性陈述 前瞻性陈述涉及一些通常或特别的已 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1833） 截至2023年12月31日止年度的經審計全年業績公告 平安健康醫療科技有限公司（「本公司」）董事會（「董事會」）欣然公佈本公司及其 附屬公司（「本集團」）截至2023年12月31日止年度經審計全年業績公告。本公告 刊載本公司2023年度報告（「年度報告」）全文，並符合香港聯合交易所有限公司 （「聯交所」）證券上市規則中有關年度業績初步公告附載的資料之要求。 本公司審計及風險管理委員會已審閱本集團截至2023年12月31日止之年度業績。 本公告將於聯交所網站 www.hkexnews.hk 及本公司網站 www.pagd.net 發佈。年度 報告將適時於上述聯交所及本公司網站發佈並送交予本公司股東。 承董事會命 平安健康醫療 ...

平安健康醫療科技有限公司 平安健康醫療科技有限公司 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED （於開曼群島註冊成立的有限公司） PING 2023 年中期報告 AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED ...

[0 -> 1] 大家早上好 [1 -> 5] 首先感谢大家参加平安健康医疗科技有限公司 [5 -> 8] 2023年中期业绩发布会 [8 -> 10] 我是本次业绩发布会的主持人 [10 -> 13] 平安健康投资者关系部负责人王亦菲 [13 -> 14] Ariel [15 -> 17] 首先请允许我为各位介绍一下 [17 -> 20] 参与本次业绩发布会的公司管理层 [21 -> 24] 他们是平安健康医疗科技有限公司 [24 -> 25] 董事会主席 [25 -> 27] 首席执行官方卫豪先生 [31 -> 35] 平安健康医疗科技有限公司总裁吴军先生 [38 -> 41] 平安健康医疗科技有限公司资深副总裁 [41 -> 44] 暨首席财务官赞洛琪女士 [47 -> 49] 本次会议将由两部分组成 [49 -> 52] 在第一部分中方卫豪先生将介绍公司 [52 -> 56] 2023年上半年的整体经营状况和业绩亮点 [56 -> 59] 之后吴军先生将为各位介绍公司 [59 -> 62] 在2023年上半年业务方面的成功实践 [63 -> 65] 最后赞洛琪女士将回顾公司 [65 -> 68] 在2 ...